Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market

ResearchMoz added Latest Research Report titled " Global Hematological Cancers Market to 2022 - Commercially Successful Targeted Therapies and Large, Innovative Pipeline to Drive Market " to it's Large Report database.

Hematological malignancies are a class of cancer that affect the blood, lymph nodes and bone marrow. They include numerous forms of leukemia, lymphoma and myeloma. Hematological malignancies constituted 9% of all newly diagnosed malignancies in the US in 2011, with data indicating lymphomas are more prevalent than leukemias or myeloma. Excluding acute lymphocytic leukemia and Hodgkin’s lymphoma, these types of malignancy are generally associated with increasing age. Therefore, considering the aging population globally, this class of malignancy is likely to become more prevalent.

Over the past 15 years, the treatment of hematological malignancies has changed significantly, with the development of targeted therapies. These developments were based on the growing understanding of the signaling pathways involved in disease pathogenesis. Notable examples include the approval of rituximab in 1997, which is used to treat multiple types of hematological malignancies, including Non-Hodgkin’s lymphoma.

Download free Sample PDF report with TOC: http://www.researchmoz.us/enquiry.php?type=S&repid=725318

Overall, there are 1,207 products in active development in the hematological cancer therapy area. The indications included in this disease cluster are classified under oncology, which is the largest therapy area in terms of pipeline products, consisting of 6,936 drugs in development. Hematological cancer has more active pipeline products than the respiratory and cardiovascular therapy areas, which indicates how active this disease cluster is in terms of product development.

Scope

The hematological cancers market is characterized by commercially successful therapies.

•     Which classes of drug dominate the market?
•     What additional benefits have newly approved therapies brought to the market?
•     How do the leading marketed therapies compare clinically?

Read All In Vitro Diagnostics Market Research Reports @ http://www.researchmoz.us/in-vitro-diagnostics-market-reports-28.html

Table of Contents

1 Table of Contents 5
1.1 List of Tables 7
1.2 List of Figures 8

2 Introduction 11
2.1 Therapy Area Introduction 11
2.2 Epidemiology 11
2.2.1 Leukemia 12
2.2.2 Lymphoma 13
2.2.3 Myeloma 14
2.3 Pathophysiology 15
2.3.1 Leukemia 15
2.3.2 Lymphoma 16
2.3.3 Myeloma 18
2.4 Symptoms 20
2.5 Diagnosis 20
2.5.1 Leukemia 20
2.5.2 Lymphoma 21
2.5.3 Myeloma 21
2.6 Prognosis and Survival 22
2.6.1 Survival 25
2.7 Treatment 25
2.7.1 Surgery and Radiation Therapy 26
2.7.2 Stem Cell Transplantation 27
2.7.3 Pharmacological Therapies 27

About ResearchMoz

ResearchMoz is the world's fastest growing collection of market research reports worldwide. Our database is composed of current market studies from over 100 featured publishers worldwide. Our market research databases integrate statistics with analysis from global, regional, country and company perspectives. ResearchMoz's service portfolio also includes value-added services such as market research customization, competitive landscaping, and in-depth surveys, delivered by a team of experienced Research Coordinators.

Contact Us:

Mr. Nachiket
Albany NY - 12207
United States
Tel: +1-518-621-2074
Tel: 866-997-4948 (Us-Canada Toll Free)
Email: sales@researchmoz.us
Follow us on LinkedIn at: http://bit.ly/1TBmnVG